This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kim PS et al. (1999) Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenetrol 94: 3254–3257
Fraser AG et al. (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485–489
Bouhnik Y et al. (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215–219
Lewis JD et al. (2000) Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118: 1018–1024
Acknowledgements
The synopsis was written by Victoria Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- CROHN'S DISEASE ACTIVITY INDEX
-
An index composed of subjective and objective parameters: a CDAI score ≤150 indicates clinical remission; >150 indicates active disease; and >450 indicates extremely severe disease
Rights and permissions
About this article
Cite this article
Ardizzone, S., Porro, G. Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission?. Nat Rev Gastroenterol Hepatol 2, 348–349 (2005). https://doi.org/10.1038/ncpgasthep0221
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0221